The European Commission says it has fined the Israeli generic drug maker, Teva, more than €460m for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine.
The European Commission says it has fined the Israeli generic drug maker, Teva, more than €460m for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine.